Trial Condition(s):

Choroidal Neovascularization

Special Drug Use Investigation of EYLEA for Myopic choroidal neovascularization

Bayer Identifier:

17416

ClinicalTrials.gov Identifier:

NCT02260687

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objectives of this study are to investigate the safety and effectiveness of EYLEA.

Inclusion Criteria
- Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization).
Exclusion Criteria
- Patients who have already received EYLEA treatment.

Trial Summary

Enrollment Goal
353
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design